Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:29212027  

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Katherine R Singleton | Lorin Crawford | Elizabeth Tsui | Haley E Manchester | Ophelia Maertens | Xiaojing Liu | Maria V Liberti | Anniefer N Magpusao | Elizabeth M Stein | Jennifer P Tingley | Dennie T Frederick | Genevieve M Boland | Keith T Flaherty | Shannon J McCall | Clemens Krepler | Katrin Sproesser | Meenhard Herlyn | Drew J Adams | Jason W Locasale | Karen Cichowski | Sayan Mukherjee | Kris C Wood
Cell reports | 2017

Diverse pathways drive resistance to BRAF/MEK inhibitors in BRAF-mutant melanoma, suggesting that durable control of resistance will be a challenge. By combining statistical modeling of genomic data from matched pre-treatment and post-relapse patient tumors with functional interrogation of >20 in vitro and in vivo resistance models, we discovered that major pathways of resistance converge to activate the transcription factor, c-MYC (MYC). MYC expression and pathway gene signatures were suppressed following drug treatment, and then rebounded during progression. Critically, MYC activation was necessary and sufficient for resistance, and suppression of MYC activity using genetic approaches or BET bromodomain inhibition was sufficient to resensitize cells and delay BRAFi resistance. Finally, MYC-driven, BRAFi-resistant cells are hypersensitive to the inhibition of MYC synthetic lethal partners, including SRC family and c-KIT tyrosine kinases, as well as glucose, glutamine, and serine metabolic pathways. These insights enable the design of combination therapies that select against resistance evolution.

Pubmed ID: 29212027

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA193256
  • Agency: NCI NIH HHS, United States
    Id: P30 CA010815
  • Agency: NCI NIH HHS, United States
    Id: R00 CA168997
  • Agency: NCI NIH HHS, United States
    Id: P50 CA174523
  • Agency: NCI NIH HHS, United States
    Id: R01 CA207083
  • Agency: NIH HHS, United States
    Id: S10 OD018164
  • Agency: NICHD NIH HHS, United States
    Id: K12 HD043446

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Agilent Technologies (tool)

RRID:SCR_013575

Company provides laboratories worldwide with analytical instruments and supplies, clinical and diagnostic testing services, consumables, applications and expertise in life sciences and applied chemical markets.

View all literature mentions